The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $87.21

Today's change+1.15 +1.34%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $87.21

Today's change+1.15 +1.34%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc up (U.S.)$1.15

Biomarin Pharmaceutical Inc closed up Wednesday by (U.S.)$1.15 or 1.34% to (U.S.)$87.21. Shares have lost 4.58% over the last five days, but have gained 23.97% over the last year to date. This security has outperformed the S&P 500 by 15.06% during the last year.

Key company metrics

  • Open(U.S.) $86.34
  • Previous close(U.S.) $86.06
  • High(U.S.) $87.83
  • Low(U.S.) $85.72
  • Bid / Ask(U.S.) $84.50 / (U.S.) $87.20
  • YTD % change+23.97%
  • Volume1,574,923
  • Average volume (10-day)1,254,810
  • Average volume (1-month)1,237,343
  • Average volume (3-month)1,199,640
  • 52-week range(U.S.) $55.04 to (U.S.) $96.36
  • Beta0.95
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.88
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-18.91%

Biomarin Pharmaceutical Inc has a net profit margin of -18.91%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX2.54%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue177192152147
Total other revenue--------
Total revenue177192152147
Gross profit147161129122
Total cost of revenue30312325
Total operating expense166211178200
Selling / general / administrative79686071
Research & development1261088697
Depreciation / amortization11112
Interest expense (income), net operating--------
Unusual expense (income)-68103
Other operating expenses, total238-9
Operating income11-20-26-53
Interest income (expense), net non-operating-9-9-9-8
Gain (loss) on sale of assets--------
Other--------
Income before tax3-28-35-59
Income after tax7-34-38-62
Income tax, total-4633
Net income7-34-38-62
Total adjustments to net income--------
Net income before extra. items7-34-38-62
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items7-34-38-62
Inc. avail. to common incl. extra. items7-34-38-62
Diluted net income8-34-38-62
Dilution adjustment000--
Diluted weighted average shares159146144143
Diluted EPS excluding extraordinary itemsvalue per share0.05-0.23-0.26-0.43
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.23-0.23-0.26-0.42